Efficacy and safety of a 28-day oral contraceptive with 7 days of low-dose estrogen in place of placebo

被引:5
作者
Poindexter, Alfred [2 ]
Reape, Kathleen Z. [1 ]
Hait, Howard [1 ]
机构
[1] Duramed Res Inc, Bala Cynwyd, PA 19004 USA
[2] Baylor Coll Med, Houston, TX 77011 USA
关键词
desogestrel; low-dose estrogen; hormone free interval; oral contraception;
D O I
10.1016/j.contraception.2008.04.001
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background: The study was conducted to evaluate the efficacy and safety for the prevention of pregnancy of a 28-day oral contraceptive (OQ containing 150 mcg desogestrel (DSG)/20 mcg ethinyl estradiol (EE) for 21 days followed by 7 days of 10 mcg EE (Cette-28). Study Design: A 6-month, prospective, multicenter, single-arm study was conducted in 1302 women aged 18-45 years. Results: Over six cycles of treatment, the cumulative risk of pregnancy among all treated subjects (n= 1262) was 0.9%. The Pearl Index for women 18-35 years of age (n=1042) was 2.20, including 9 pregnancies with estimated conception dates during active drug ingestion or up to 7 days after the last combination tablet. The rate of unscheduled bleeding was low and the duration of scheduled bleeding was approximately 2 days during each of the six treatment cycles. The safety profile was similar to what has been reported for other OCs. Conclusion: This low-dose, 28-day OC incorporating 7 days of 10 mcg EE during the hormone free interval is effective and safe for the prevention of pregnancy and is well-tolerated by women. (0 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 16 条
  • [1] *ACOG, 2003, ACOG PRACT B, V42
  • [2] Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol
    Anderson, FD
    Gibbons, W
    Portman, D
    [J]. CONTRACEPTION, 2006, 73 (03) : 229 - 234
  • [3] Evaluation of a continuous regimen of levonorgestrel/ethinyl estradiol: phase 3 study results
    Archer, David F.
    Jensen, Jeffrey T.
    Johnson, Julia V.
    Borisute, Hannah
    Grubb, Gary S.
    Constantine, Ginger D.
    [J]. CONTRACEPTION, 2006, 74 (06) : 439 - 445
  • [4] Baerwald Angela R, 2004, J Obstet Gynaecol Can, V26, P19
  • [5] Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use
    Baerwald, AR
    Olatunbosun, OA
    Pierson, RA
    [J]. CONTRACEPTION, 2004, 70 (05) : 371 - 377
  • [6] Calle EE, 1996, LANCET, V347, P1713, DOI 10.1016/S0140-6736(96)90806-5
  • [7] *DUR RES INC, 1998, 20713 NDA DUR RES IN
  • [8] Manipulation of human ovarian function: Physiological concepts and clinical consequences
    Fauser, BCJM
    VanHeusden, AM
    [J]. ENDOCRINE REVIEWS, 1997, 18 (01) : 71 - 106
  • [9] Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioners' oral contraception study
    Hannaford, Philip C.
    Selvaraj, Sivasubramaniam
    Elliott, Alison M.
    Angus, Valerie
    Iversen, Lisa
    Lee, Amanda J.
    [J]. BRITISH MEDICAL JOURNAL, 2007, 335 (7621): : 651 - 654A
  • [10] Ovarian activity in women taking an oral contraceptive containing 20 μg ethinyl estradiol and 150 μg desogestrel:: Effects of low estrogen doses during the hormone-free interval
    Killick, SR
    Fitzgerald, C
    Davis, A
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1998, 179 (01) : S18 - S24